2022
DOI: 10.1007/s10753-022-01662-9
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 45 publications
0
1
0
Order By: Relevance
“…A salient finding in this study is the differential impact of IFN-β and B12 combination therapy on miR-106a and let-7c, both of which have previously been implicated in inflammation and autoimmune responses [2,3]. Cobalamin notably decreases miR-106a expression, resulting in enhanced IL-10 levels, and consequently reducing pro-inflammatory cytokines such as IL-17, IL-22, and TNF-α.…”
Section: Commentarymentioning
confidence: 77%
See 1 more Smart Citation
“…A salient finding in this study is the differential impact of IFN-β and B12 combination therapy on miR-106a and let-7c, both of which have previously been implicated in inflammation and autoimmune responses [2,3]. Cobalamin notably decreases miR-106a expression, resulting in enhanced IL-10 levels, and consequently reducing pro-inflammatory cytokines such as IL-17, IL-22, and TNF-α.…”
Section: Commentarymentioning
confidence: 77%
“…Multiple Sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is a complex disorder affecting millions globally, which necessitates innovative therapeutic strategies [1]. In the quest for novel treatments, we have conducted a recent study that has provided crucial insights into the potential synergistic effects of interferonbeta (IFN-β) and cobalamin (Vitamin B12) in MS therapy, targeting interleukin-10 (IL-10), osteopontin (OPN), and specific microRNAs (miR-106a, let-7c, and miR-146a] [2,3]. This comprehensive exploration has added a substantial layer of understanding to the field of MS therapeutics, elucidating the potential role of cobalamin as a viable adjuvant to established IFN-β therapy.…”
Section: Commentarymentioning
confidence: 99%
“…During acute demyelination, blood-derived lymphocytes and monocyte-derived macrophages respond to florid infiltration of CNS parenchyma, which is accompanied by significant BBB dysfunction and a strong glial response, eventually leading to demyelination and axonal destruction [ 18 , 19 , 20 ]. It has been suggested that genes expressed in peripheral blood can be utilized to study MS [ 17 , 21 , 22 , 23 ]. More importantly, there are indications that ferroptosis may play a role in BBB dysfunction, although the exact mechanism remains unclear [ 24 ].…”
Section: Introductionmentioning
confidence: 99%